Merck & Company Inc (MRK)vsRepligen Corporation (RGEN)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
RGEN
Repligen Corporation
$165.18
+0.30%
HEALTHCARE · Cap: $9.51B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 8379% more annual revenue ($66.57B vs $785.10M). RGEN leads profitability with a 5.3% profit margin vs 4.8%. RGEN appears more attractively valued with a PEG of 1.67. RGEN earns a higher WallStSmart Score of 39/100 (F).
MRK
Hold36
out of 100
Grade: F
RGEN
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+12.4%
Fair Value
$159.07
Current Price
$165.18
$6.11 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
No standout strengths identified
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Expensive relative to growth rate
ROE of 2.4% — below average capital efficiency
5.3% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : RGEN
Revenue growth of 11.9% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : RGEN
The primary concerns for RGEN are PEG Ratio, Return on Equity, Profit Margin. A P/E of 227.7x leaves little room for execution misses.
Key Dynamics to Monitor
RGEN carries more volatility with a beta of 1.05 — expect wider price swings.
RGEN is growing revenue faster at 11.9% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RGEN scores higher overall (39/100 vs 36/100) and 11.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Repligen Corporation
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?